Levosimendan Versus Dobutamine in Shock Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-10-31

Study Completion Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to compare the efficacy of levosimendan with that of dobutamine in patients with unstable hemodynamics (shock).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiogenic Shock Septic Shock

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Shock Levosimendan Inotropes Dobutamine Heart failure Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Levosimendan

Intervention Type DRUG

Dobutamine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Reduced left ventricular systolic function
* Hypotension
* Anuria or oligouria

Exclusion Criteria

* Less than 18 years old
* Pregnant
* Uncorrected valvular stenosis
* Hypertrophic obstructive cardiomyopathy (HOCM)
* Third degree AV block

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Intensive Care Unit, Nepean Hospital

Penrith, New South Wales, Australia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Australia

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Anthony S McLean, MD

Role: primary

Stephen J Huang, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

03/007

Identifier Type: -

Identifier Source: org_study_id